Mantell Associates

As North Carolina’s biopharma hotbed enjoys an onshoring investment rush, clinical-stage vaccine developer Vaxcyte is the latest company to put down manufacturing roots in the state. Read more below: https://lnkd.in/erQVXZjZ #pharmanews #pharmaproduction #pharmamanufacturing

In a merger between two subcutaneous drug delivery companies, Halozyme, Inc. is paying $750 million in cash to acquire Elektrofi. Read more below: https://lnkd.in/ekW-87NZ. #pharmamerger #pharmanews #pharmaacquisition

Don't just listen to us, listen to what our clients have to say! A recent recommendation for Vincent Mackay, Head of our Biologics and Cell & Gene Therapy division from a long-standing partner. "From the moment I met Vincent at a CGT conference in Washington, it was evident that Mantell Associates stood head and shoulders above the rest. Their expertise in recruiting top-tier talent in the fiercely competitive cell and gene therapy market is unmatched, delivering a seamless, efficient, and remarkably swift process that exceeded our expectations. We entrusted Mantell Associates with a formidable challenge: a complete manufacturing site buildout in China, spanning from General Manager/Site Head to a large cohort of operators, technicians, and specialists. In just under 90 days, they delivered the entire brief with precision and professionalism. So impressed were we by their dedication and the value they provided, that we subsequently engaged them for two full commercial team buildouts in the United States and another in Europe, each executed with the same exceptional standard. I wholeheartedly recommend Mantell Associates to my network and beyond. Their proven track record in delivering successful project builds across the CGT industry speaks volumes. For any organization considering this investment, my advice is unequivocal: choose Mantell Associates every time." Contact Vincent Mackay to discuss your business requirements at +44 (0)20 3854 7700. #recruitmentpharma #biotechrecruitment #cellandgenerecruitment

Genmab is continuing to build up its pipeline of wholly owned late-stage cancer assets, this time paying $8 billion for Netherlands-based Merus N.V. and its bispecific antibody. Read more below: https://lnkd.in/gH3gpYna #biotechnews #bispecific #clinicaltrials

Serial entrepreneur Róbert Wessman, who has had a golden touch creating, acquiring and spinning off companies that primarily sell generic drugs, has brought together two of his fastest-growing enterprises as Lotus Pharmaceuticals has acquired a 100% equity stake in Alvogen. Read more below: https://lnkd.in/deg-Qt2M #pharmanews #pharmaacquisition #generics

Big Pharma's U.S. manufacturing investment pledges continue to pile up on the mainland and beyond. In the industry's latest nine-figure capital investment project, Amgen plans a $650 million expansion of its sprawling site in Juncos, Puerto Rico. Read more below: https://lnkd.in/d--vpNMC #pharmamanufacturing #pharmanews #puertorico

New opportunity! Sales Representative - Pharma - Switzerland. Mantell Associates is partnered with a well-established Pharmaceutical company, known for its high-quality generic and OTC product portfolio, who is seeking a motivated Sales Representative to support its growth in the Swiss market. Apply for this role online - https://lnkd.in/dSJ4T6Pq - or contact Millie Bone on +44 (0)20 3854 7700. #salesjobs #pharmasales #pharmajobs

GATTEFOSSÉ, a provider of specialty ingredients and formulation solutions for personal care and pharmaceutical industries, has opened its new manufacturing facility in Lufkin, Texas. Read more below: https://lnkd.in/e4bdAnWq #manufacturing #pharmamanufacturing #oharmaproduction

uniQure has set its sights on submitting its Huntington’s disease gene therapy for approval next year after the asset was shown to slow progression of the neurodegenerative condition by 75% in a phase 1/2 trial. Read more below: https://lnkd.in/g-KAfjde #genetherapy #biotechnews #clinicaltrials

Angelini Pharma has worked out a $550 million-plus biobucks deal to get its hands on a Korean biotech’s preclinical neuro asset. Read more below: https://lnkd.in/eBSUrD8x #biotechnews #biotech #preclinicalnews